Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus

Abstract

Patients with systemic lupus erythematosus (SLE) are susceptible to the development of lymphoproliferative disorders and postulated causes include intrinsic defects in immune surveillance and iatrogenic administration of immunosuppressants. Since the introduction of mycophenolate mofetil (MMF) to the immunosuppressive regimen for the management of post-organ transplantation, there have been reports of primary lymphoma of the central nervous system (PCNSL). MMF has been widely used to treat active SLE patients with Class IV lupus nephritis. In addition to two previously reported cases of PCNSL among SLE patients on long-term MMF, we report a third patient who has been on treatment with MMF for 8 years. The histology showed features compatible with diffuse large B-cell lymphoma with strong immunohistochemical staining for CD20 and positive signal for Epstein—Barr virus (EBV)-encoded RNA by in-situ hybridization that is similar to other case reports, suggesting EBV driven B-cell lymphoproliferative disease. The patient responded to withdrawal of MMF, intravenous methotrexate, rituximab and whole brain radiotherapy. With the increasing use of MMF in active renal as well as non-renal exacerbations of SLE, PCNSL should be included in the differential diagnosis in patients who present with gradual onset of focal neurological deficit.

Keywords

Epstein—Barr virus immunosuppression lymphoma mycophenolate mofetil systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Batara JF , Grossman SA Primary central nervous system lymphomas. Curr Opin Neurol 2003; 16: 671-675.

Dasgupta N. , Gelber AC , Racke F. , Fine DM Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 2005; 14: 910-913.

Finelli PF , Naik K. , DiGiuseppe JA , Prasad A. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus 2005; 15: 886-888.

O’Neill BP , Vernino S. , Dogan A. , et al. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol 2007; 9: 364-369.

Bernatsky S. , Ramsey-Goldman E. , Rajan R. , et al. Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1507-1509.

Mellemkjaer L. , Andersen V. , Linet MS , et al. Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 761-768.

Snanoudj R. , Durrbach A. , Leblond V. , et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation 2003; 76: 830-837.

Ramos-Casals M. , Brito-Zeron P. , Yague J. , et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with Sjogren’s syndrome . Rheumatology 2005; 44: 89-94.

Opelz G. , Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003; 4: 222-230.

10.

Evans SJ , Watson DK , O’Sullivan M. Reversible Hodgkin’s lymphoma associated with Epstein-Barr virus occurring during azathioprine therapy for SLE. Rheumatology 2008; 47: 1103-1104.